Brett, T and Radford, J and Heal, C and Hespe, CM and Garton-Smith, J and Kirke, A and Chan, DC and Pang, J and Watts, GF, Implications of new clinical practice guidance on familial hypercholesterolaemia for Australian general practitioners, Australian Journal of General Practice, 50, (9) pp. 616-621. ISSN 2208-7958 (2021) [Review Single Work]
Background: Familial hypercholesterolaemia (FH) is a monogenic lipid disorder that may be overlooked in the diagnostic process.
Objective: The aim of this article is to review the key areas for identification and management of FH that affect Australian general practitioners (GPs).
Discussion: Recent consensus advice on the care of patients with FH in Australia provides an opportunity for GPs to increase their awareness and skills in diagnosing and managing FH. New Medicare Benefits Schedule items for genetic testing and Pharmaceutical Benefits Scheme listing for the use of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors offer GPs additional supports to improve the care of patients with FH. A shared-care approach between GPs and non-GP specialists with expertise in multiple disciplines offers the best option to facilitate genetic testing and management of index cases and affected family relatives. Implementation of this guidance in the primary care setting remains an ongoing challenge and needs to be embraced as a high priority.
|Item Type:||Review Single Work|
|Keywords:||Familial Hypercholesterolaemia, general practice, preventive healthcare, atherosclerotic cardiovascular disease, cascade testing, genetic disease, screening|
|Research Division:||Biomedical and Clinical Sciences|
|Research Group:||Cardiovascular medicine and haematology|
|Research Field:||Cardiology (incl. cardiovascular diseases)|
|Objective Group:||Clinical health|
|Objective Field:||Prevention of human diseases and conditions|
|UTAS Author:||Radford, J (Professor Jan Radford)|
|Web of Science® Times Cited:||2|
Repository Staff Only: item control page